Work Here?
Overview
Seer provides a platform for proteomics by combining its Proteograph system with proprietary nanoparticles and software to enable deep, unbiased, and rapid analysis of the proteome. It captures proteins from complex biological samples using specially designed nanoparticles and then analyzes them with software to identify and quantify proteins, giving researchers a more complete view of protein expression. The platform is used across drug discovery, diagnostics, and basic research, with a business model that includes selling the Proteograph system as well as recurring revenue from consumables and software. Seer's approach stands apart from competitors by delivering broader, more comprehensive proteome coverage through its nanoparticle-based capture combined with data analysis, enabling quicker, more thorough proteomic insights. The company aims to become a leading tool for researchers to gain biological insights and support development in life sciences, genomics, and multi-omics.
About Seer
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2017
Get referred to Seer
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose sequentially to $3.1 million, with consumable pull-through improving.
- Management reaffirmed $16 million-$18 million 2026 guidance and reported $209.5 million cash.
- In June 2026, PTAB and EPO upheld Seer patent claims against challengers.
What critics are saying
- Q2 2026 revenue fell 23% year over year, exposing weak academic and government demand.
- Radoff-JEC’s June 2026 proxy fight targets three directors and frames management as entrenched.
- If revenue stays near $3 million quarterly, Seer burns cash before Proteograph adoption scales.
What makes Seer unique
- Seer’s Proteograph uses proprietary nanoparticles and mass spectrometry for deep, unbiased plasma proteomics.
- In August 2026, Seer cited 250 patents, including 84 issued core claims.
- Its 20,000-sample Korea University collaboration and 10,000-protein HuBP atlas strengthen adoption.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$344.5M
Above
Industry Average
Funded Over
6 Rounds
Benefits
Performance Bonus
Company Equity
Stock Options
Remote Work Options
Stock Price
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 0%2 year growth
↑ 0%Seer reported revenue of $3.1 million for the second quarter of 2026, a 23% decrease from $4.1 million in the prior year period. The company attributed the decline to macroeconomic headwinds affecting academic and government funding, along with extended customer evaluations. The proteomics company posted a net loss of $16.9 million for the quarter, compared to $19.4 million in the year-ago period. Operating expenses decreased 19% to $18.3 million, primarily due to lower employee compensation costs. Seer ended the quarter with approximately $209.5 million in cash, cash equivalents, and investments. The company repurchased roughly 200,000 Class A common shares during the period. Seer reaffirmed its full year 2026 revenue guidance of $16 million to $18 million, representing 3% growth over 2025.
Seer (NASDAQ:SEER) issues quarterly earnings results, misses estimates by $0.04 EPS. August 11, 2026 Key points. * Seer missed quarterly expectations: The company reported an adjusted loss of $0.31 per share, $0.04 worse than analysts' estimate, while revenue of $3.10 million fell short of the $3.55 million consensus. * Profitability remains weak: Seer posted a negative 26.58% return on equity and a negative net margin of 464.78%, highlighting continued operating losses. * Analyst sentiment is mixed but leans positive: The stock has a consensus "Buy" rating and a $4.00 average price target, although one analyst maintained a "Sell" rating. Institutional investors own 75.20% of the shares. * MarketBeat previews the top five stocks to own by September 1st. Seer (NASDAQ:SEER - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.04), FiscalAI reports. Seer had a negative return on equity of 26.58% and a negative net margin of 464.78%.The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.55 million. Seer stock performance. NASDAQ SEER remained flat at $2.16 on Tuesday. 199,128 shares of the company's stock traded hands, compared to its average volume of 644,225. The business has a 50-day moving average of $1.94 and a two-hundred day moving average of $1.88. The company has a market capitalization of $118.76 million, a PE ratio of -1.74 and a beta of 1.55. Seer has a fifty-two week low of $1.55 and a fifty-two week high of $2.41. Institutional inflows and outflows. Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Seer by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,221,404 shares of the company's stock worth $4,820,000 after acquiring an additional 18,760 shares during the period. Bridgeway Capital Management LLC lifted its stake in Seer by 15.5% during the 2nd quarter. Bridgeway Capital Management LLC now owns 837,443 shares of the company's stock valued at $1,792,000 after acquiring an additional 112,100 shares during the period. Geode Capital Management LLC lifted its stake in Seer by 16.5% during the 2nd quarter. Geode Capital Management LLC now owns 509,727 shares of the company's stock valued at $1,091,000 after acquiring an additional 72,265 shares during the period. Jane Street Group LLC boosted its holdings in shares of Seer by 33.3% in the 1st quarter. Jane Street Group LLC now owns 254,174 shares of the company's stock valued at $430,000 after acquiring an additional 63,432 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Seer by 2.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 235,485 shares of the company's stock valued at $431,000 after acquiring an additional 6,304 shares during the last quarter. 75.20% of the stock is owned by institutional investors and hedge funds. Wall Street analysts forecast growth. A number of research analysts have recently commented on the stock. TD Cowen upgraded shares of Seer to a "strong-buy" rating in a report on Monday, April 13th. Canaccord Genuity Group began coverage on shares of Seer in a research note on Monday, May 4th. They issued a "buy" rating and a $4.00 price objective for the company. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Seer in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Seer currently has a consensus rating of "Buy" and an average target price of $4.00. Seer company profile. Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer's platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine. The company's flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Seer, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seer wasn't on the list. While Seer currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Enter your email address and we'll send you MarketBeat's list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Seer Inc. faces fraud investigation: investor alert. A big red flag for Seer shareholders. The name of the game today is trust, and the folks over at Seer, Inc. (NASDAQ: SEER) might be on the verge of having theirs shattered. Schall, Brown & Schwartz LLP (SBS) decided to roll out the heavy artillery with an investigation targeting Seer's potential securities violations. It's like watching a tightrope walker lose their balance - suspenseful and nerve-wracking. Who's keeping an eye on this? Investors should be. Did Seer pull the wool over investors' eyes? Now, get this - the probe's centered around allegations that Seer might've dished out some less-than-accurate statements or maybe skipped out on revealing crucial bits of info. Investors Hangout, LLC is talking about stuff that, if true, can rip a portfolio apart faster than you can say 'shareholder lawsuit.' So, it's not just smoke and mirrors; it's about whether someone swapped the mirrors for smoke entirely. "When you're trading, you're not just dealing in stocks - you're dealing in trust," echoed a sentiment many of Investors Hangout, LLC have experienced. What should investors be watching? If you're holding onto a piece of the Seer pie, it might be time to sharpen those pencils and crunch some numbers yourself. SBS is opening the doors for investors who've taken a hit to join the fray and seek some justice - or at least a good old-fashioned accounting redemption. Consider this your call to arms. What SBS brings to the table. Look, SBS isn't messing around. You have Brian Schall and his partners, Andrew Brown and David Schwartz, hustling from Los Angeles to pave the way for shareholders like you. These guys aren't greenhorns; they've been in the securities class action trenches long enough to know how to handle what's thrown at them. They've pledged to fight like cornered bulls for shareholder rights. That's no small feat in the cutthroat world of financial litigation. The importance of accountability. The thing is, there's a bigger narrative here. Investors need to remember the weight of corrective action on market stability. It's not just about someone's stack of shares - it's about market integrity. When a company like Seer potentially fudges the facts, it's not all about cracking knuckles and reclaiming dollars. It's resetting the scale for truth. Your move, shareholders. Feeling fired up? You should be. This isn't just another ignorable headline - it's about what lies beneath the dollar signs. You can reach out to SBS for a chat and toss your hat into the ring. Whether on legal flair or moral grounds, stand up for those invested pennies. So, don't sit on your hands. The future's knocking, and it sure sounds like SBS wants to open the door wide. If there's something to be gleaned here, it's that you can't afford to be passive. Keep those eyes peeled and ears open - because in the world of stocks, it's all about staying one step ahead of the game. The clock is ticking, folks, and the wise ones are already dialed into asking questions. Better get hustling.
Seer shares jumped 30% following an investor presentation filed ahead of its 28 July annual meeting. The proteomics company highlighted its expanding installed customer base, which has grown at a 62% compound annual rate since 2021, and outlined a total addressable market estimated at $23 billion by 2034. Seer reported improved financials, with annual cash burn down 36% since 2022 and reduced operating expenses. The company holds approximately $220 million in cash with no debt. The board authorised a $50 million share buyback programme, with $25.5 million remaining available. Stock-based compensation has fallen roughly 75% since 2023 to an estimated $8.5 million run rate in 2026. Seer faces a proxy contest, with the board urging shareholders to support its seven nominees.
The Radoff-JEC Group, holding approximately 7.7% of Seer, Inc., has urged stockholders to vote for boardroom change, citing significant value destruction since the company's December 2020 initial public offering. The group claims Seer's share price has declined 97% whilst CEO Omid Farokhzad received nearly $37 million in compensation. The activists highlight cumulative losses exceeding $465 million and minimal revenue growth despite $160 million in investments. They criticise the board for rejecting three acquisition proposals offering 33-42% premiums and note the company's strategic plan doesn't anticipate profitability until 2031. The Radoff-JEC Group proposed settling the proxy contest through governance enhancements and a tender offer for 20 million shares at $2.50 each, but reports the board has not responded. The group is backing three director nominees.
Seer is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Seer
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Redwood City, California
Founded
2017
Seer is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today